| Lenalidomide induces ubiquitination and degradation of CK1α in del (5q) MDS J Krönke, EC Fink, PW Hollenbach, KJ MacBeth, SN Hurst, ND Udeshi, ... Nature 523 (7559), 183-188, 2015 | 800 | 2015 |
| Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome KA Donovan, J An, RP Nowak, JC Yuan, EC Fink, BC Berry, BL Ebert, ... Elife 7, e38430, 2018 | 349 | 2018 |
| The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K M Słabicki, Z Kozicka, G Petzold, YD Li, M Manojkumar, RD Bunker, ... Nature 585 (7824), 293-297, 2020 | 252 | 2020 |
| The novel mechanism of lenalidomide activity EC Fink, BL Ebert Blood, The Journal of the American Society of Hematology 126 (21), 2366-2369, 2015 | 174 | 2015 |
| Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia M Järås, PG Miller, LP Chu, RV Puram, EC Fink, RK Schneider, ... Journal of Experimental Medicine 211 (4), 605-612, 2014 | 101 | 2014 |
| Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice EC Fink, M McConkey, DN Adams, SD Haldar, JA Kennedy, AA Guirguis, ... Blood, The Journal of the American Society of Hematology 132 (14), 1535-1544, 2018 | 87 | 2018 |
| Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs AS Sperling, M Burgess, H Keshishian, JA Gasser, S Bhatt, M Jan, ... Blood, The Journal of the American Society of Hematology 134 (2), 160-170, 2019 | 52 | 2019 |
| Saccharomyces cerevisiae Esc2p interacts with Sir2p through a small ubiquitin-like modifier (SUMO)-binding motif and regulates transcriptionally silent chromatin in a locus … Q Yu, H Kuzmiak, L Olsen, A Kulkarni, E Fink, Y Zou, X Bi Journal of biological chemistry 285 (10), 7525-7536, 2010 | 20 | 2010 |
| Degradation of GSPT1 causes TP53-independent cell death in leukemia while sparing normal hematopoietic stem cells RS Sellar, AS Sperling, M Słabicki, JA Gasser, ME McConkey, ... The Journal of Clinical Investigation 132 (16), 2022 | 19 | 2022 |
| Lenalidomide induces ubiquitination and degradation of CSNK1A1 in MDS with Del (5q) EC Fink, J Krönke, SN Hurst, ND Udeshi, T Svinkina, RK Schneider, ... Blood 124 (21), 4, 2014 | 18 | 2014 |
| Compositions and methods for selecting a treatment for b-cell neoplasias BL Ebert, SA Carr, J Krönke, ND Udeshi, E Fink US Patent App. 15/034,490, 2016 | 7 | 2016 |
| IMiD screening methods IMiD-sensitive cells with mutant CRBN BL Ebert, J Krönke, SA Carr, ND Udeshi, E Fink US Patent 10,334,829, 2019 | 5 | 2019 |
| Knock-in rodent comprising a mutation in an endogenous CRBN locus and methods of use thereof BL Ebert, J Krönke, SA Carr, ND Udeshi, E Fink US Patent 9,974,289, 2018 | 2 | 2018 |
| Knock-in rodent comprising a mutation in an endogenous crbn locus and methods of use thereof BL Ebert, J Krönke, SA Carr, ND Udeshi, E Fink US Patent App. 16/408,792, 2019 | 1 | 2019 |
| BRAF and MC1R in melanoma: different in head and neck tumors? EC Fink, DE Fisher Journal of Investigative Dermatology 133 (4), 878-880, 2013 | 1 | 2013 |
| Disease biomarkers and treatment methods related thereto BL Ebert, J Krönke, SA Carr, ND Udeshi, E Fink US Patent 11,785,925, 2023 | | 2023 |
| The Search for Endogenous Lenalidomide in Cell Lines EC Fink | | 2020 |
| Author response: Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome KA Donovan, J An, RP Nowak, JC Yuan, EC Fink, BC Berry, BL Ebert, ... (No Title), 2018 | | 2018 |
| Investigating the Mechanism and Species-Specificity of Thalidomide Derivatives EC Fink Harvard University, 2018 | | 2018 |
| Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice Short title: Crbn I391V mice respond to thalidomide derivatives EC Fink, M McConkey, DN Adams, SD Haldar, JA Kennedy, AA Guirguis, ... | | 2018 |
